Evidence map›Paper›PMID 34833022›Full record

ArticleLife (Basel, Switzerland)2021

A Multiallelic Molecular Beacon-Based Real-Time RT-PCR Assay for the Detection of SARS-CoV-2.

Andreas C Chrysostomou, Johana Hezka Rodosthenous, Cicek Topcu, Christina Papa, Antonia Aristokleous, Georgia Stathi, Christina Christodoulou, Christina Eleftheriou, Dora C Stylianou, Leondios G Kostrikis

Open access · goldAbstract read
In one paragraph

Article in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Virology Applications to the COVID-19 Pandemic.Life (Basel, Switzerland) · 2025
    Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Andreas C ChrysostomouDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.ORCID 0000-0002-5796-1588
Johana Hezka RodosthenousDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Cicek TopcuDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Christina PapaDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Antonia AristokleousDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Georgia StathiDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Christina ChristodoulouDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.ORCID 0000-0001-6136-4113
Christina EleftheriouDepartment of Health and Safety, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Dora C StylianouDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.
Leondios G KostrikisDepartment of Biological Sciences, University of Cyprus, Aglantzia, Nicosia 2109, Cyprus.ORCID 0000-0002-5340-7109
University of Cyprus · CY

Funding

European Regional Development Fund and the Republic of Cyprus through the Cyprus Research and Innovation Foundation and the Structural Funds 2021-2027 Project: CONCEPT-COVID_0420_0024University of Cyprus "Research Saves Lives" campaign
6 · The paper itself

Abstract

Emerging infectious viruses have led to global advances in the development of specific and sensitive detection techniques. Viruses have an inherent potential to easily mutate, presenting major hurdles for diagnostics and requiring methods capable of detecting genetically diverse viral strains. One such infectious agent is severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which emerged in December 2019 and has resulted in the global coronavirus disease 2019 (COVID-19) pandemic. This study presents a real-time reverse transcription PCR (RT-PCR) detection assay for SARS-CoV-2, taking into account its intrinsic polymorphic nature that arises due to genetic drift and recombination, as well as the possibility of continuous and multiple introductions of genetically nonidentical strains into the human population. This advance was achieved by using mismatch-tolerant molecular beacons designed to specifically detect the SARS-CoV-2 S, E, M, and N genes. These were applied to create a simple and reproducible real-time RT-PCR assay, which was validated using external quality control panels (QCMD: CVOP20, WHO: SARS-CoV-2-EQAP-01) and clinical samples. This assay was designed for high target detection accuracy and specificity and can also be readily adapted for the detection of other emerging and rapidly mutating pathogens.

Indexed as

COVID-19molecular beaconsSARS-CoV-2

Identifiers

PMID34833022
PMCPMC8619337
OpenAlexW3210960883

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.